A Pioneer's Overview of Cannabinoids: From Ancient Use to Modern Medicine
Raphael Mechoulam, who first isolated THC, reviewed the field from ancient Assyrian and Chinese use through modern clinical applications in chemotherapy nausea, appetite loss, multiple sclerosis, and neuroprotection.
Quick Facts
What This Study Found
The review traced cannabinoid science from historical use in Assyria and China through to the identification of CB1 and CB2 receptors and the discovery of endogenous cannabinoids. THC had established clinical utility as an anti-vomiting and appetite-enhancing agent. Clinical work in multiple sclerosis was advancing toward potential drug approval.
CBD, described as a non-psychotropic constituent, was showing promise in preclinical studies. Recent animal model work on CBD in rheumatoid arthritis suggested potential clinical applications. A synthetic cannabinoid called HU-211 (Dexanabinol) was in advanced clinical trials as a neuroprotectant for head trauma.
Key Numbers
No specific statistical data were presented in this overview.
How They Did This
This was a narrative review by Raphael Mechoulam, one of the founding researchers in cannabinoid science, covering the historical, pharmacological, and clinical landscape of cannabinoid research. It synthesized findings from preclinical and clinical studies across multiple therapeutic areas.
Why This Research Matters
Written by the researcher who first isolated and synthesized THC in 1964, this review carried unique authority. It documented the state of cannabinoid science at a transitional moment when the basic pharmacology was established but clinical applications were still being developed. The mention of CBD for rheumatoid arthritis and synthetic cannabinoids for neuroprotection pointed toward research directions that would expand significantly.
The Bigger Picture
Mechoulam's review anticipated several developments that materialized in subsequent years: THC-based medications gained broader approval, CBD became the basis for Epidiolex (approved for epilepsy in 2018), and the endocannabinoid system became a major focus of neuroscience research. However, Dexanabinol (HU-211) did not ultimately achieve regulatory approval for head trauma.
What This Study Doesn't Tell Us
As a broad overview by a single researcher, this paper provided perspective rather than systematic analysis. The review covered many therapeutic areas briefly rather than deeply. Some of the promising research directions described did not pan out as anticipated.
Questions This Raises
- ?Why did Dexanabinol fail to achieve regulatory approval despite advanced clinical trials?
- ?How did Mechoulam's framing of cannabinoid research influence funding and regulatory priorities in subsequent decades?
Trust & Context
- Key Stat:
- Review by Raphael Mechoulam, who first isolated THC in 1964
- Evidence Grade:
- This is a narrative review by a leading researcher that synthesizes findings across multiple areas, providing moderate-level evidence through expert synthesis.
- Study Age:
- Published in 2001, this review captures the state of cannabinoid medicine before the major clinical trial era of the 2000s and 2010s.
- Original Title:
- The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection.
- Published In:
- Pain research & management, 6(2), 67-73 (2001)
- Authors:
- Mechoulam, R(10), Hanu, L
- Database ID:
- RTHC-00109
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Who is Raphael Mechoulam?
Raphael Mechoulam is an Israeli organic chemist who first isolated and synthesized THC in 1964, and later helped discover the endocannabinoid system. He is widely considered the founding father of cannabinoid research.
What happened with the neuroprotection drug mentioned in this review?
Dexanabinol (HU-211), the synthetic cannabinoid being tested for head trauma neuroprotection, went through clinical trials but did not ultimately achieve regulatory approval, illustrating how promising preclinical results do not always translate to approved treatments.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- entourage-effect-whole-plant-cannabis
- full-spectrum-vs-broad-spectrum-vs-isolate
- cannabis-and-ibs-gut-health-inflammation
- cannabis-and-crohns-disease-gastroenterology
Cite This Study
https://rethinkthc.com/research/RTHC-00109APA
Mechoulam, R; Hanu, L. (2001). The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection.. Pain research & management, 6(2), 67-73.
MLA
Mechoulam, R, et al. "The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection.." Pain research & management, 2001.
RethinkTHC
RethinkTHC Research Database. "The cannabinoids: an overview. Therapeutic implications in v..." RTHC-00109. Retrieved from https://rethinkthc.com/research/mechoulam-2001-the-cannabinoids-an-overview
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.